In The Media…
Hospital & Healthcare Management
December 16, 2021
The risk of infection with the transperineal approach to prostate biopsy is nearly 0%. As a result, adoption of the PrecisionPoint™ Transperineal Access System has the potential to help ease the economic burden associated with treating infections caused by the transrectal approach. Dr. Matthew Allaway, founder and CEO of Perineologic, explains in this HHM Global (Hospital & Healthcare Management) article.